Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Can J&J's Innovative Medicines Unit Sustain Growth Amid Stelara LOE?
10:01am, Monday, 16'th Jun 2025
JNJ's Innovative Medicines unit shows a growth trend, defying Stelara LOE and the negative impact of the Part D redesign.
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal potential of novel, off-the-shelf ap
Johnson & Johnson CEO: 'We're in the Golden Era of Medical Innovation'
08:06am, Saturday, 14'th Jun 2025
Johnson & Johnson Chairman and CEO Joaquin Duato believes that we are now in a “golden era” of innovation, particularly in the United States. Venture capital plays a vital early-stage role, but bi
Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
11:00am, Friday, 13'th Jun 2025
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate
Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Pha
Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
05:54pm, Wednesday, 11'th Jun 2025
Johnson & Johnson (NYSE:JNJ ) Goldman Sachs 46th Annual Global Healthcare Conference Call June 11, 2025 3:20 PM ET Company Participants Tom Cavanaugh - Company Group Chairman for North America Innovat
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
10:56am, Wednesday, 11'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
10:40am, Wednesday, 11'th Jun 2025
JNJ edges ahead of MRK with stronger 2025 growth prospects, a broader pipeline and better sales momentum despite key headwinds.
TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study More than 40% of TREMFYA®-treated patients across both do
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
05:00am, Wednesday, 11'th Jun 2025
Volatility is a part of life for long-term investors. The reasons the market goes up or down change, but the constant is that high-quality stocks, businesses that increasingly make more money over tim
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
04:51pm, Tuesday, 10'th Jun 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. “We are thrilled to have
3 Top Dividend Stocks Analysts Are Bullish on Right Now
07:39am, Friday, 06'th Jun 2025
We're at the end of earnings season. That means it's time for analysts to weigh in on the outlook for specific stocks.
Make an Easy $2,852 in Passive Income By Invest $25,000 in These Dividend Stocks Today
10:30am, Thursday, 05'th Jun 2025
Key Points Put your money to work. Make it make you money. It can make you a good deal of consistent money if you invest wisely in higher-yielding Dividend King stocks. Are you ahead, or behind on ret
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
10:06am, Thursday, 05'th Jun 2025
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
I have invested in dividends for 15 years—These are the foundations of my passive income plan
04:10pm, Wednesday, 04'th Jun 2025
Key Points These high-yield dividend stocks haven’t disappointed me in the last decade. Each of these stocks have the potential of an upside as the economy improves. Are you ahead, or behind on reti
